IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancer
#5PRI RANKED
Most Cited Paper
in Growth Hormone and Insulin-like Growth Factors
18 Months Post-Publication
Class of 2026
“IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancer”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
Insulin-like growth factor binding protein 2 · ITGA5 · gefitinib resistance · STAT3 · CXCL1 · Non-small cell lung cancer · Non-small cell lung cancer · EGFR-sensitive mutations · acquired resistance · non-EGFR secondary mutations · bronchoalveolar lavage fluid · transcriptional activation · biomarker · STAT3/CXCL1 axis · IGFBP2/ITGA5 axis
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Growth Hormone and Insulin-like Growth Factors Papers, Class of 2026. https://pri.pepkio.com/top-papers/growth-hormone-and-insulin-like-growth-factors/2026. Accessed 2026-10-24. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459